Clinical Trial ResultsCERE announced positive Phase 3 TEMPO-3 study data for tavapadon, a treatment for Parkinson's disease, meeting its primary endpoint and showing a significant increase in 'on' time without troublesome dyskinesia.
Financial StrategyABBV's recent bond sale to fund its acquisitions is a strong financial move, increasing confidence in the successful completion of the CERE deal.
Merger And AcquisitionThe proposed acquisition of CERE by AbbVie is expected to close, indicating continued progress towards the merger and suggesting a potential upside for CERE's share price.